EA200301319A1 - Противоопухолевые комбинации - Google Patents

Противоопухолевые комбинации

Info

Publication number
EA200301319A1
EA200301319A1 EA200301319A EA200301319A EA200301319A1 EA 200301319 A1 EA200301319 A1 EA 200301319A1 EA 200301319 A EA200301319 A EA 200301319A EA 200301319 A EA200301319 A EA 200301319A EA 200301319 A1 EA200301319 A1 EA 200301319A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumor
combinations
tumor combinations
published
combination
Prior art date
Application number
EA200301319A
Other languages
English (en)
Other versions
EA007530B1 (ru
Inventor
Гари Дьюкарт
Джеймс Джозеф мл. Гиббонс
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уайт filed Critical Уайт
Publication of EA200301319A1 publication Critical patent/EA200301319A1/ru
Publication of EA007530B1 publication Critical patent/EA007530B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предусматривает применение комбинации ингибитора mTOR и противоопухолевого алкилирующего агента для лечения новообразований.Отчет о международном поиске был опубликован 2003.03.13.
EA200301319A 2001-06-01 2002-05-29 Противоопухолевые комбинации EA007530B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (2)

Publication Number Publication Date
EA200301319A1 true EA200301319A1 (ru) 2004-04-29
EA007530B1 EA007530B1 (ru) 2006-10-27

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301319A EA007530B1 (ru) 2001-06-01 2002-05-29 Противоопухолевые комбинации

Country Status (17)

Country Link
EP (1) EP1392286A2 (ru)
JP (1) JP2004532883A (ru)
KR (1) KR100875611B1 (ru)
CN (1) CN100496485C (ru)
AU (2) AU2002259309B2 (ru)
BR (1) BR0210101A (ru)
CA (1) CA2447732A1 (ru)
CO (1) CO5540294A2 (ru)
EA (1) EA007530B1 (ru)
HU (1) HUP0400006A2 (ru)
IL (1) IL158800A0 (ru)
MX (1) MXPA03010907A (ru)
NO (1) NO20035317L (ru)
NZ (1) NZ529877A (ru)
PL (1) PL367267A1 (ru)
SG (1) SG153647A1 (ru)
WO (1) WO2002098416A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066019A2 (en) 2001-02-19 2002-08-29 Novartis Ag Cancer treatment
UA83484C2 (ru) * 2003-03-05 2008-07-25 Уайт Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
TW200803892A (en) * 2005-11-04 2008-01-16 Wyeth Corp Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
KR20140012218A (ko) 2005-11-21 2014-01-29 노파르티스 아게 Ｍｔｏｒ 억제제를 사용하는 신경내분비 종양 치료법
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
CN101415409B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
SI2131821T1 (sl) * 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
NZ590464A (en) 2008-08-04 2012-10-26 Wyeth Llc Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
KR20160106211A (ko) 2009-04-06 2016-09-09 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
SG43072A1 (en) * 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
WO2002066019A2 (en) * 2001-02-19 2002-08-29 Novartis Ag Cancer treatment

Also Published As

Publication number Publication date
HUP0400006A2 (hu) 2004-04-28
SG153647A1 (en) 2009-07-29
NZ529877A (en) 2006-08-31
AU2008202690A1 (en) 2008-07-10
AU2002259309B2 (en) 2008-05-01
CN1646120A (zh) 2005-07-27
MXPA03010907A (es) 2004-02-17
BR0210101A (pt) 2004-06-08
NO20035317L (no) 2003-12-22
JP2004532883A (ja) 2004-10-28
EA007530B1 (ru) 2006-10-27
CO5540294A2 (es) 2005-07-29
WO2002098416A2 (en) 2002-12-12
NO20035317D0 (no) 2003-11-28
KR100875611B1 (ko) 2008-12-24
CA2447732A1 (en) 2002-12-12
IL158800A0 (en) 2004-05-12
CN100496485C (zh) 2009-06-10
PL367267A1 (en) 2005-02-21
KR20040025923A (ko) 2004-03-26
EP1392286A2 (en) 2004-03-03
WO2002098416A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
EA200301319A1 (ru) Противоопухолевые комбинации
BR0016878A (pt) Inibidores tricìclicos de cinases protéicas
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
EA200501251A1 (ru) Антинеопластические комбинации
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
EA199800667A1 (ru) Новые фенантридины
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
DE69728585D1 (de) Mittel gegen Juckreiz
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
DE69738286D1 (de) Spreizspektrumwasserzeichen für integrierte Signalisierung
EA200400029A1 (ru) КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА АЛЬДОСТЕРОНА И ИНГИБИТОРА ГМГ-КоА-РЕДУКТАЗЫ
EA200301100A1 (ru) Новые фталазиноны
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
ATE406159T1 (de) Behandlung von hyperlipidämie
DE69921139D1 (de) Phtalazine derivate phosphodiesterase 4 inhibitoren
ATE386742T1 (de) Imidazonaphthyridine
ECSP034866A (es) Combinaciones antineoplásticas
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
DE60127131D1 (de) Tricyclische imidazopyridine
DE60025494D1 (de) Epothilon zusammensetzungen
SE0302361D0 (sv) Inhibering av upptagning av monoamin
EA200200798A1 (ru) Кальцилитические соединения
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EA200500878A1 (ru) Кальцилитические соединения
EA200300061A1 (ru) Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина и алкилирующих агентов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU